Weight Loss In Obese Subjects Taking Either GW869682 Or Placebo 3 Times Per Day For 12 Weeks

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

136 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-01-31

Study Completion Date

2006-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

GW869682 causes glucose to be excreted in the urine. The purpose of this study is to see whether enough calories from glucose are excreted in the urine to cause weight loss.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs

NCT00494767

Diabetes Mellitus, Type 2 Obesity

COMPLETED PHASE1

A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes

NCT02097277

Diabetes Mellitus Type 2

COMPLETED PHASE2

A 35 Day Study to Investigate the Effects of GSK1521498 on Bodyweight in Obese Subjects With Over-Eating Behaviours.

NCT01195792

Obesity

COMPLETED PHASE2

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist

NCT06500429

Overweight and Obesity Healthy

COMPLETED PHASE2

Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions

NCT06867718

Obesity or Overweight

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GW869682

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have a BMI within range 30.0 to 40.0kg/m2, inclusive.
* Females who meet above criteria must be physiologically incapable of becoming pregnant (ie., surgically sterilized, or post-menopausal per protocol definition).

Exclusion Criteria

* History of eating disorders.
* Recent history of weight loss or gain.
* Had gastrointestinal surgery for treatment of obesity.
* Type 1 or type 2 diabetes mellitus.
* Have a positive urine drug screen.
* Have liver disease.
* Have hepatitis B, hepatitis C, or HIV antibodies.
* Have a thyroid disorder that is not under control with medication.
* Have any disease (such as heart, liver, blood, nervous system, or kidney disease, or cancer).
* Are unable to participate in an exercise program.
* Have used weight loss drugs within 3 months before the start of the study.
* Are currently using warfarin, digoxin, oral anti-coagulants (other than aspirin and non-steroidal anti-inflammatory drugs), oral or injectable corticosteroids (inhaled \& intranasal corticosteroids are permitted), or antiretroviral medications.
* Used of any investigational drug or device during the study or within 30 days prior to 1st dosing of study medication.
* High or low blood pressure.

Minimum Eligible Age

18 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes